Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02936843 · ClinicalTrials.gov registry record · Phase 2
Targeting Inflammation With Salsalate in Type 1 Diabetes Neuropathy
A Phase 2 study, sponsored by University of Michigan.
- Completed
- Registry status
- Phase 2
- Development phase
- 61
- Enrollment target
NCT02936843 is a Phase 2 study that has completed, run by University of Michigan. The registered enrollment target is 61 participants.
The verdict
NCT02936843, a Phase 2 study, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 61 participants
- Enrollment target
Study Summary
Diabetic neuropathy (DN) is the most common chronic complication of diabetes, affecting up to50% of individuals with type 1 diabetes (T1DM). Multiple pre-clinical and clinical studies demonstrate a pathogenic role for inflammation, especially cytokine production, in the disease course of DN and CAN. This suggests that agents with known anti-inflammatory properties, such as salicylates, may prevent the development of DN and the pain associated with DN. This study builds upon and expands on prior work done by the investigators with salsalate, a pro-drug form of salicylate, as an agent to address inflammatory pathways in people with T1DM.
Interventions
- DRUG PLACEBO
- DRUG Salsalate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2016-10 |
| Est. Completion | 2023-05-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02936843
The ClinicalTrials.gov registry entry for NCT02936843 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which PLACEBO is the first listed.
NCT02936843 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02936843 about?
NCT02936843 is a clinical study titled "Targeting Inflammation With Salsalate in Type 1 Diabetes Neuropathy". Diabetic neuropathy (DN) is the most common chronic complication of diabetes, affecting up to50% of individuals with type 1 diabetes (T1DM). Multiple pre-clinical and clinical studies demonstrate a pathogenic role for inflammation, especially cytokine production, in the disease course of DN and CAN...
What is the current status of trial NCT02936843?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2016-10. Estimated completion is 2023-05-01.
What interventions are being tested in trial NCT02936843?
The interventions under investigation include: PLACEBO (DRUG), Salsalate (DRUG).
Who is sponsoring clinical trial NCT02936843?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.